These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31373232)

  • 1. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
    Jiang L; Xu W; Chen Y; Zhang Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in
    Fanini F; Bandini E; Plousiou M; Carloni S; Wise P; Neviani P; Murtadha M; Foca F; Fabbri F; Vannini I; Fabbri M
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.
    Bhatt V; Lan T; Wang W; Kong J; Lopes EC; Wang J; Khayati K; Raju A; Rangel M; Lopez E; Hu ZS; Luo X; Su X; Malhotra J; Hu W; Pine SR; White E; Guo JY
    Cell Death Dis; 2023 Jan; 14(1):61. PubMed ID: 36702816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.
    Molina-Arcas M; Hancock DC; Sheridan C; Kumar MS; Downward J
    Cancer Discov; 2013 May; 3(5):548-63. PubMed ID: 23454899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
    Prahallad A; Weiss A; Voshol H; Kerr G; Sprouffske K; Yuan T; Ruddy D; Meistertzheim M; Kazic-Legueux M; Kottarathil T; Piquet M; Cao Y; Martinuzzi-Duboc L; Buhles A; Adler F; Mannino S; Tordella L; Sansregret L; Maira SM; Graus Porta D; Fedele C; Brachmann SM
    Cancer Res; 2023 Dec; 83(24):4130-4141. PubMed ID: 37934115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.
    Wong GS; Zhou J; Liu JB; Wu Z; Xu X; Li T; Xu D; Schumacher SE; Puschhof J; McFarland J; Zou C; Dulak A; Henderson L; Xu P; O'Day E; Rendak R; Liao WL; Cecchi F; Hembrough T; Schwartz S; Szeto C; Rustgi AK; Wong KK; Diehl JA; Jensen K; Graziano F; Ruzzo A; Fereshetian S; Mertins P; Carr SA; Beroukhim R; Nakamura K; Oki E; Watanabe M; Baba H; Imamura Y; Catenacci D; Bass AJ
    Nat Med; 2018 Jul; 24(7):968-977. PubMed ID: 29808010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition.
    Adderley H; Blackhall FH; Lindsay CR
    EBioMedicine; 2019 Mar; 41():711-716. PubMed ID: 30852159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells.
    Rodrigues FS; Miranda VS; Carneiro-Lobo TC; Scalabrini LC; Kruspig B; Levantini E; Murphy DJ; Bassères DS
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.
    Tomasini P; Walia P; Labbe C; Jao K; Leighl NB
    Oncologist; 2016 Dec; 21(12):1450-1460. PubMed ID: 27807303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies.
    Liu Z; Liu Y; Qian L; Jiang S; Gai X; Ye S; Chen Y; Wang X; Zhai L; Xu J; Pu C; Li J; He F; Huang M; Tan M
    Mol Cell; 2021 Oct; 81(19):4076-4090.e8. PubMed ID: 34375582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors.
    Sahu P; Mitra A; Ganguly A
    Int Rev Cell Mol Biol; 2024; 386():167-222. PubMed ID: 38782499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
    Lu X; Yu R; Li Z; Yang M; Dai J; Liu M
    Cancer Lett; 2024 Feb; 582():216517. PubMed ID: 38101609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ERBB network facilitates KRAS-driven lung tumorigenesis.
    Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
    Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.
    Zhang H; Nabel CS; Li D; O'Connor RÍ; Crosby CR; Chang SM; Hao Y; Stanley R; Sahu S; Levin DS; Chen T; Tang S; Huang HY; Meynardie M; Stephens J; Sherman F; Chafitz A; Costelloe N; Rodrigues DA; Fogarty H; Kiernan MG; Cronin F; Papadopoulos E; Ploszaj M; Weerasekara V; Deng J; Kiely P; Bardeesy N; Vander Heiden MG; Chonghaile TN; Dowling CM; Wong KK
    J Thorac Oncol; 2023 Jul; 18(7):882-895. PubMed ID: 36958689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting MEK in non-small cell lung cancer.
    Lara MS; Blakely CM; Riess JW
    Curr Probl Cancer; 2024 Apr; 49():101065. PubMed ID: 38341356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS
    Cai C; Yao S; Zou Y; Lu H; Chen X; Wang Y; Zheng K; Zhu F; Wang Y; Xiong H; Zhu J
    J Cell Mol Med; 2023 Jun; 27(12):1637-1652. PubMed ID: 37226642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.
    Kumar MS; Hancock DC; Molina-Arcas M; Steckel M; East P; Diefenbacher M; Armenteros-Monterroso E; Lassailly F; Matthews N; Nye E; Stamp G; Behrens A; Downward J
    Cell; 2012 Apr; 149(3):642-55. PubMed ID: 22541434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin.
    Guo Y; Tian J; Guo Y; Wang C; Chen C; Cai S; Yu W; Sun B; Yan J; Li Z; Fan J; Qi Q; Zhang D; Jin W; Hua Z; Chen G
    Cell Rep; 2023 Dec; 42(12):113511. PubMed ID: 38043062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers.
    Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
    J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of KRAS by SETD7 promotes KRAS degradation in non-small cell lung cancer.
    Chiang CY; Fan S; Zheng H; Guo W; Zheng Z; Sun Y; Zhong C; Zeng J; Li S; Zhang M; Xiao T; Zheng D
    Cell Rep; 2023 Sep; 42(9):113003. PubMed ID: 37682707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.